Tag Archives: Photodynamic therapy

Photodynamic Therapy of an Abdominal Abscess at the Time of Percutaneous Drainage

July 18, 2023 by Modulight
No comments
Published in: Cardiovascular and Interventional Radiology Authors: Timothy M. Baran, Ashwani Kumar Sharma    Published in: Cardiovascular and Interventional Radiology Authors: Timothy M. Baran, Ashwani Kumar Sharma   This article presents a successful case study from an ongoing Phase 1 clinical trial where methylene blue together with ML7710 is used to eradicate bacteria and biofilm in the treatment of persistent abscesses. The potential of Photodynamic Therapy (PDT) is explored as an adjunct treatment for recurrent or challenging-to-manage abdominal abscesses during percutaneous drainage procedures. Despite advancements in abscess drainage techniques and antibiotics, some cases exhibit low response rates and recurrences, Continue reading →

Laser platform and light delivery optimization for bladder cancer treatment with a novel photosensitive drug

March 14, 2023 by Modulight
No comments
Presented in: SPIE BIOS 2023 Authors: Zoe Ylöniemi, Elias Kokko, Visa Kaivosoja, Ana Colucci, Eerika Suokas, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Zoe Ylöniemi, Elias Kokko, Visa Kaivosoja, Ana Colucci, Eerika Suokas, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.   Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – February 2022

March 2, 2022 by Modulight Content
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – February 2022 Photocure’s blue light cystoscopy is a routine procedure in the management of bladder cancer as it results in better tumor visualization and removal. However, this study found that the positive effects of blue light cystoscopy could extend beyond visualization and result in the induction of systemic antitumor immunity, which can be further boosted with immune checkpoint inhibitors. Modulight nominated this study because bladder cancer is highly recurring and progressive disease with more than 200,000 deaths worldwide annually. Thus, Continue reading →

Nanobody-targeted photodynamic therapy for the treatment of feline oral carcinoma: a step towards translation to the veterinary clinic

August 2, 2021 by Modulight
No comments
Published in: Nanophotonics Authors: Irati Beltrán Hernández, Guillaume C.M. Grinwis, Alessia Di Maggio, Paul M.P. van Bergen en Henegouwen, Wim E. Hennink, Erik Teske, Jan W. Hesselink, Sebastiaan A. van Nimwegen, Jan A. Mol, Sabrina Oliveira    Published in: Nanophotonics Authors: Irati Beltrán Hernández, Guillaume C.M. Grinwis, Alessia Di Maggio, Paul M.P. van Bergen en Henegouwen, Wim E. Hennink, Erik Teske, Jan W. Hesselink, Sebastiaan A. van Nimwegen, Jan A. Mol, Sabrina Oliveira   Nanobody-targeted PDT was shown in vitro to be suitable and efficient for oral carcinoma, which expresses EGFR. Modulight laser was used as an illumination source to activate PDT. Next aim is to treat cats with oral carcinoma before advancing to human clinic.   Read the article here

ML7710 for glioblastoma treatment

May 25, 2021 by Modulight Content
No comments
Background   Professor Stummer on glioblastoma surgeries and iPDT:   Treatment protocol 20 patients were treated. 5-ALA (Gliolan) was administered at a dosage of 20 mg/kg body weight 4 hours before anesthesia. Craniotomy was performed using FGR, with aim of maximal safe resection of the fluorescent tumor. Once there was no visible fluorescence or only tumor-infiltrated fluorescence in the eloquent areas left, PDT was performed. 1-4 cylindrical diffuser were strategically inserted depending on the size and architecture of the resection cavity and fixed to a Continue reading →Customer case Research by: University Hospital Münster provides cutting-edge medical treatments for patients all over the world. The department of neurosurgery provides a full spectrum of neurosurgical care with interdisciplinary vascular and neuro-oncological specialization. Modulight products: ML7710, ML7710i Laser use: Randomized controlled PDT trials for both newly diagnosed and recurrent glioblastoma, as well as compassionate care for terminal glioblastoma patients. Link to the study: Professor Walter Stummer, MD, PhD Research topics: Professor Stummer is a world leader in his research fields, which include vascular neurosurgery, microneurosurgery, Continue reading →

New Insights on Management of CSCR

May 1, 2021 by Modulight
No comments
Retinal Physician – May 1, 2021  Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight.Retinal Physician - May 1, 2021  Currently, most retina specialists use photodynamic therapy (PDT) with verteporfin (Visudyne; Bausch + Lomb). Photodynamic therapy devices include ML6710i (available for investigational use only in the United States) by Modulight and ML7710 (CE certified; available for investigational use only in the United States) by Modulight. Read article

Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy

August 3, 2020 by Modulight
No comments
Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland    Published in: Chemical Science Authors: John A. Roque III, Patrick C. Barrett, Houston D. Cole, Liubov M. Lifshits, Ge Shi, Susan Monro, David von Dohlen, Susy Kim, Nino Russo, Gagan Deep, Colin G. Cameron, Marta E. Alberto, Sherri A. McFarland   ML8500 was used for specialized dosimetry studies in the development of the osmium-based PS using similar drug development strategy as for the analogous Ru(II) series that resulted in TLD1433 (first metal complex in clinical trials). The Os-compound approaches the ideal properties with multi-wavelength activation Continue reading →

Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors

May 8, 2020 by Modulight
No comments
Published in: Communications Biology Authors: Kensuke Kaneko, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, Cong-Xiao Liu, Márcio A. Diniz, Khaldon Bodoor, Philip F. Hughes, Timothy AJ. Haystead, H. Kim Lyerly    Published in: Communications Biology Authors: Kensuke Kaneko, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, Cong-Xiao Liu, Márcio A. Diniz, Khaldon Bodoor, Philip F. Hughes, Timothy AJ. Haystead, H. Kim Lyerly   ML7710 was used for in vivo and ML8500 coupled to ML7710 for in vitro studies of HSP90-targeted verteporfin PDT for breast cancer. This strategy has both diagnostic and therapeutic potential across all breast cancer subtypes found up to few cm in depth, and may provide Continue reading →

Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells

August 10, 2019 by Modulight
No comments
Published in: Cancer Letters Authors: Yan Baglo, Barry J. Liang, Robert W. Robey, Suresh V. Ambudkar, Michael M. Gottesman, Huang-Chiao Huang    Published in: Cancer Letters Authors: Yan Baglo, Barry J. Liang, Robert W. Robey, Suresh V. Ambudkar, Michael M. Gottesman, Huang-Chiao Huang   They have used laser to study PDT resistance mechanisms by activating BPD photosensitizer in cancer cell lines and subsequently determining the cell viabilities. The lipidation of BPD is shown to decrease its efflux from cells and increase PDT effectiveness.   Read the article here

Modulight becomes exclusive supplier for BAUSCH + LOMB

December 4, 2018 by Seppo Orsila
No comments
BRIDGEWATER, N.J., December 04, 2018 – Bausch + Lomb, a leading global eye health company, and Modulight, Inc., a designer and manufacturer of lasers and optics for personalized medicine, announced the companies have entered into an exclusive agreement to collaborate and develop a new photodynamic laser specifically designed for use with Bausch + Lomb’s VISUDYNE® (verteporfin for injection) therapy. “Photodynamic therapy continues to be an important option for eye care professionals who treat choroidal neovascularization in patients who suffer from persistent disease activity, but the availability of lasers capable Continue reading →